290例药物性肝损伤患者临床特征分析*

doi:10.3969/j.issn.1672-5069.2020.04.022

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (4): 540-543.doi: 10.3969/j.issn.1672-5069.2020.04.022

290例药物性肝损伤患者临床特征分析^*

何文昌, 张克恭, 赵凡惠, 郭芮杉, 高禄化, 黄长形, 王临旭

710038 西安市空军军医大学第二附属医院感染病科/全军感染病诊疗中心

收稿日期:2019-07-30 发布日期:2020-07-15
通讯作者: 王临旭,E-mail: wanglx@fmmu.edu.cn
作者简介:何文昌,男,规范化培训医师。主要从事药物性肝损害临床诊治研究。E-mail:1832758640@qq.com
基金资助:
*陕西省自然科学基金资助项目(编号:2014JM2-8151);空军军医大学科技发展基金资助项目(编号:学2016XD257)

Clinical feature of 290 patients with drug-induced liver injury

He Wenchang, Zhang Kegong, Zhao Fanhui, et al

Department of Infectious Diseases, Second Affiliated Hospital, Air Force Medical University, Xi’an 710038, Shaanxi Province, China

Received:2019-07-30 Published:2020-07-15

摘要/Abstract

摘要： 目的探讨药物性肝损伤(DILI)患者的病因构成、临床特点和预后情况。方法 2013年1月～2016年2月我科诊治的300例DILI患者,根据Roussel Uclaf因果关系(RUCAM)量表评估。结果经RUCAM量表评分诊断为DILI患者290例;引起DILI的药物为中药,占42.8%,抗菌药和抗结核药物分别占9.3%和7.6%;基础疾病以胃炎最为多见,占18.6%;肝细胞型占54.5%;中度肝损伤占37.6%;肝衰竭发生率为5.5%,治疗有效率为93.8%,死亡4例。结论应用RUCAM量表有助于DILI的规范化诊断,中药导致的肝损伤不可忽视,大部分DILI患者临床预后较好,少数发生急性肝衰竭,预后差,应引起高度重视。

关键词: 药物性肝损伤, Roussel Uclaf因果关系量表, 临床特点, 预后

Abstract: Objective The purpose of this study was to investigate the clinical feature of 290 patients with drug-induced liver injury (DILI). Methods 300 hospitalized patients were admitted in our Department of Infectious Diseases from January 2013 through February 2016, and 290 were diagnosed as DILI by the Roussel Uclaf causality assessment (RUCAM) scale. Results The common agents were traditional Chinese medicine, accounting for 42.8%, antibiotics for 9.3% and anti-tuberculosis medicines for 7.6%; the elevated serum alanine aminotransferase levels was the most obvious manifestation; the underlying diseases were chronic gastritis in 18.6%, the hepatocellular injury type accounted for 54.5% and the moderate DILI accounted for 37.6%; 16 patients 5.5% progressed to liver failure and four died; the total treatment effective rate was 93.8%. Conclusion The RUCAM scale is helpful for the standardization of DILI diagnosis. The traditional Chinese medicines account for the highest proportion of liver injuries in our series, and the hepatocellular damage is the most common type. Most DILI patients have a good clinical prognosis. Attentions should be paid to patients with acute liver failure, which is associated with poor prognosis.

Key words: Drug-induced liver injury, RUCAM scale, Clinical features, Prognosis

何文昌, 张克恭, 赵凡惠, 郭芮杉, 高禄化, 黄长形, 王临旭. 290例药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 540-543.

He Wenchang, Zhang Kegong, Zhao Fanhui, et al. Clinical feature of 290 patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2020, 23(4): 540-543.

参考文献

[1]Bjornsson ES,Bergmann OM,Bjornsson HK,et al. Incidence, presentation,and outcomes in patients with drug-induced liver injury in the general populationofIceland. Gastroenterology, 2013,144(7):1419-1425.
[2]Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis,2014,34(2):115-122.
[3]Tailor A, Faulkner L,Naisbitt DJ, et al. The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. Hum Exp Toxicol, 2015,34(12):1310-1307.
[4]Shen T, Liu YX, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China, Gastroenterology, 2019, 156(8):2230-2241.
[5]Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 2008, 135(6):1921-1934.
[6]Tailor A, Faulkner L,Naisbitt DJ, et al. The chemical, genetic and immunological basis ofidiosyncratic drug-induced liver injury. Hum Exp Toxicol, 2015,34(12):1310-1307.
[7]Hayashi PH, Bjornsson ES. Long-term outcomes after drug-Induced liver injury. Curr Hepatol Rep, 2018,17(3):292-299.
[8]Zhu CW, Wang HN, Yuan JL, et al. Clinical features of drug-induced liver injury : an analysis of 445 cases. J Clin Hepatol, 2018,2(34):354-358.
[9]Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol, 1990,11(2):272-276.
[10]Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci, 2015,17(1):14.
[11]Chalasani N P, Hayashi P H, Bonkovsky H L, et al. ACG clinical guideline: the diagnosis and management of Idiosyncratic drug-Induced Liver Injury. Am J Gastroenterol, 2014, 109(7):950-966.
[12]于乐成,茅益民,陈成伟.药物性肝损伤诊治指南.实用肝脏病杂志,2017,20(2):257-274.
[13]朱斌,章福彬,刘卫,等.药物性肝损害88例临床分析.实用肝脏病杂志,2008,11(6):396-397.
[14]Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology (Baltimore, Md), 2008,48(4):1175-1183.
[15]Hutchinson T A, Lane D A. Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol, 1989,42(1):5-16.
[16]Rathi C, Pipaliya N, Patel R, et al. Drug induced liver Injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality. Ann Hepatol, 2017,16(3):442-450.
[17]Isa SE, Ebonyi AO, Shehu NY, et al. Antituberculosisdrugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Int J Mycobacteriol, 2016,5(1):21-26.
[18]Zhang K, Dong XM, Wang Q, et al. Research progress on metabolism and toxicology of hepatotoxic components in common Chinese materia medica. Chin Tradit Herb Drugs, 2018,49(22):5435-5447.
[19]Haque T, Sasatomi E, Hayashi PH.Drug-induced liver injury: Pattern recognition and future directions.Gut Liver, 2016,10(1):27-36.
[20]Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med, 2002,137:947-954.

290例药物性肝损伤患者临床特征分析^*

Clinical feature of 290 patients with drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李侗曾, 孔明, 宋文艳, 徐曼曼, 陈煜, 全国疑难及重症肝病攻关协作组. 慢加急性肝衰竭患者第三腰椎骨骼肌指数与临床指标的关系^*[J]. 实用肝脏病杂志, 2020, 23(4): 467-470.
[2]	罗凌,邓万玉,彭蕾,张振华,邹桂舟. 肝衰竭患者血浆置换治疗后血清胆红素和凝血酶原活动度变化规律浅探[J]. 实用肝脏病杂志, 2020, 23(3): 384-387.
[3]	王红学, 朱清静, 张玉娟, 毛重山. 异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*[J]. 实用肝脏病杂志, 2020, 23(2): 227-230.
[4]	王玮, 杜晓菲, 路运健. 术前NLR水平对TACE联合MWA治疗的巨块型原发性肝癌患者生存时间的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 260-263.
[5]	李天纵, 周松, 周石. 肝细胞癌患者TACE治疗前后血清miR-145水平变化及其临床意义[J]. 实用肝脏病杂志, 2020, 23(2): 264-267.
[6]	王建辉, 郭红丹, 孔晶晶, 武希润. 抗结核药物致药物性肝损伤患者临床特点及其危险因素分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 58-61.
[7]	杨慧玲, 刘小静, 何英利, 杜粉静, 叶峰. 失代偿期乙型肝炎肝硬化患者发生医院感染临床特点及危险因素分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 78-81.
[8]	吴欣, 郭杨志, 杜霄壤, 吴孟晋, 朱云, 冯兴中. 75例中药诱导的肝损伤患者临床特征分析*[J]. 实用肝脏病杂志, 2019, 22(5): 668-671.
[9]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[10]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[11]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[12]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[13]	刘立伟,赵新颜. 药物性肝损伤临床与组织病理学特点[J]. 实用肝脏病杂志, 2019, 22(2): 160-163.
[14]	黄春洋,单晶,廖慧钰,黄云丽,韩莹,张小丹,杜晓菲,任美欣,边新渠,刘燕敏. 甲基强的松龙治疗药物性肝损伤患者临床及实验室特点分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 208-211.
[15]	吴秀欣,张惠勇,张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 212-215.